Literature DB >> 19003916

Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls.

Pietro Invernizzi1, Carlo Selmi, Francesca Poli, Sara Frison, Annarosa Floreani, Domenico Alvaro, Piero Almasio, Floriano Rosina, Marco Marzioni, Luca Fabris, Luigi Muratori, Lihong Qi, Michael F Seldin, M Eric Gershwin, Mauro Podda.   

Abstract

Genetic factors are critical in determining susceptibility to primary biliary cirrhosis (PBC), but there has not been a clear association with human leukocyte antigen (HLA) genes. We performed a multicenter case-control study and analyzed HLA class II DRB1 associations using a large cohort of 664 well-defined cases of PBC and 1992 controls of Italian ancestry. Importantly, healthy controls were rigorously matched not only by age and sex, but also for the geographical origin of the proband four grandparents (Northern, Central, and Southern Italy). After correction for multiple testing, DRB1*08 [odds ratio (OR), 3.3; 95% confidence interval (CI), 2.4-4.5] and DRB1*02 (OR 0.9; 95% CI 0.8-1.2) were significantly associated with PBC, whereas alleles DRB1*11 (OR 0.4; 95% CI 0.3-0.4) and DRB1*13 (OR 0.7; 95% CI 0.6-0.9) were protective. When subjects were stratified according to their grandparental geographical origin, only the associations with DRB1*08 and DRB1*11 were common to all three areas. Associated DRB1 alleles were found only in a minority of patients, whereas an additive genetic model is supported by the gene dosage effect for DRB1*11 allele and the interaction of DRB1*11,*13, and *08. Lastly, no significant associations were detected between specific DRB1 alleles and relevant clinical features represented by the presence of cirrhosis or serum autoantibodies. In conclusion, we confirm the role for HLA to determine PBC susceptibility and suggest that the effect of HLA is limited to patient subgroups. We suggest that a large whole-genome approach is required to identify further genetic elements contributing to the loss of tolerance in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003916      PMCID: PMC2592501          DOI: 10.1002/hep.22567

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

1.  Performing the exact test of Hardy-Weinberg proportion for multiple alleles.

Authors:  S W Guo; E A Thompson
Journal:  Biometrics       Date:  1992-06       Impact factor: 2.571

2.  Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.

Authors:  P Invernizzi; A Crosignani; P M Battezzati; G Covini; G De Valle; A Larghi; M Zuin; M Podda
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

3.  Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease.

Authors:  H Payami; S Joe; N R Farid; V Stenszky; S H Chan; P P Yeo; J S Cheah; G Thomson
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

Review 4.  The immunogenetics of human infectious diseases.

Authors:  A V Hill
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

5.  Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection.

Authors:  L Alric; M Fort; J Izopet; J P Vinel; J P Charlet; J Selves; J Puel; J P Pascal; M Duffaut; M Abbal
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

6.  Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.

Authors:  T D de Gruijl; H J Bontkes; J M Walboomers; P Coursaget; M J Stukart; C Dupuy; E Kueter; R H Verheijen; T J Helmerhorst; M F Duggan-Keen; P L Stern; C J Meijer; R J Scheper
Journal:  J Gen Virol       Date:  1999-02       Impact factor: 3.891

7.  HLA-DRB1*1301 and *1302 protect against chronic hepatitis B.

Authors:  T Höhler; G Gerken; A Notghi; R Lubjuhn; H Taheri; U Protzer; H F Löhr; P M Schneider; K H Meyer zum Büschenfelde; C Rittner
Journal:  J Hepatol       Date:  1997-03       Impact factor: 25.083

8.  Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia.

Authors:  M R Thursz; D Kwiatkowski; C E Allsopp; B M Greenwood; H C Thomas; A V Hill
Journal:  N Engl J Med       Date:  1995-04-20       Impact factor: 91.245

9.  Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type 1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression.

Authors:  S Itescu; S Rose; E Dwyer; R Winchester
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

10.  Common west African HLA antigens are associated with protection from severe malaria.

Authors:  A V Hill; C E Allsopp; D Kwiatkowski; N M Anstey; P Twumasi; P A Rowe; S Bennett; D Brewster; A J McMichael; B M Greenwood
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

View more
  54 in total

1.  Selected human leukocyte antigen class II polymorphisms and risk of adult glioma.

Authors:  Bryan A Bassig; Peter D Inskip; Laurie Burdette; William R Shapiro; Robert G Selker; Howard A Fine; Jay S Loeffler; Peter M Black; Robert Dubrow; Alina V Brenner
Journal:  J Neuroimmunol       Date:  2010-12-30       Impact factor: 3.478

Review 2.  Cutting-edge issues in primary biliary cirrhosis.

Authors:  Marco Folci; Francesca Meda; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 3.  Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.

Authors:  Pietro Invernizzi
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

4.  Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis.

Authors:  Guanghua Rong; Renqian Zhong; Ana Lleo; Patrick S C Leung; Christopher L Bowlus; Guo-Xiang Yang; Chen-Yen Yang; Ross L Coppel; Aftab A Ansari; Dean A Cuebas; Howard J Worman; Pietro Invernizzi; Gregory J Gores; Gary Norman; Xiao-Song He; M Eric Gershwin
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

Review 5.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 6.  Update on primary biliary cirrhosis.

Authors:  Pietro Invernizzi; Carlo Selmi; M Eric Gershwin
Journal:  Dig Liver Dis       Date:  2010-03-31       Impact factor: 4.088

7.  Lack of association between vitamin D receptor gene ApaI, BsmI, and TaqI polymorphisms and primary biliary cirrhosis risk: a meta-analysis.

Authors:  Cuiju Mo; Yu Lu; Yan Deng; Jian Wang; Li Xie; Taijie Li; Yu He; Xue Qin; Shan Li
Journal:  Tumour Biol       Date:  2014-02-14

8.  Familial clustering and genetic background of primary biliary cirrhosis in Japan.

Authors:  Masatoshi Yanagisawa; Hitoshi Takagi; Hitomi Takahashi; Masahiro Uehara; Toshiyuki Otsuka; Kazuhisa Yuasa; Kenichi Hosonuma; Masatomo Mori
Journal:  Dig Dis Sci       Date:  2009-12-11       Impact factor: 3.199

9.  Genomic variants associated with primary biliary cirrhosis.

Authors:  Carlo Selmi; Natalie J Torok; Andrea Affronti; M Eric Gershwin
Journal:  Genome Med       Date:  2010-01-26       Impact factor: 11.117

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.